Send to

Choose Destination
Arrhythm Electrophysiol Rev. 2013 Nov;2(2):82-90. doi: 10.15420/aer.2013.2.2.82.

What About Tachycardia-induced Cardiomyopathy?

Author information

Clinical Fellow, Harvard Medical School, Beth Israel Deaconess Medical Center.
Herman C. Dana Professor of Medicine, Harvard Medical School, Chief of the Cardiovascular Division, Beth Israel Deaconess Medical Center and Director, Harvard-Thorndike Electrophysiology Institute and Arrhythmia Service, Beth Israel Deaconess Medical Center, Boston, US.


Long-standing tachycardia is a well-recognised cause of heart failure and left ventricular dysfunction, and has led to the nomenclature, tachycardia-induced cardiomyopathy (TIC). TIC is generally a reversible cardiomyopathy if the causative tachycardia can be treated effectively, either with medications, surgery or catheter ablation. The diagnosis is usually made after demonstrating recovery of left ventricular function with normalisation of heart rate in the absence of other identifiable aetiologies. One hundred years after the first reported case of TIC, our understanding of the pathophysiology of TIC in humans remains limited despite extensive work in animal models of TIC. In this review we will discuss the proposed mechanisms of TIC, the causative tachyarrhythmias and their treatment, outcomes for patients diagnosed with TIC, and future directions for research and clinical care.


Tachycardia-induced cardiomyopathy; atrial fibrillation; cardiomyopathy; premature ventricular contractions; supraventricular tachycardia; tachycardia-mediated cardiomyopathy; ventricular tachycardia

Supplemental Content

Full text links

Icon for Radcliffe Cardiology Icon for PubMed Central
Loading ...
Support Center